BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Goldberg RM, Sargent DJ, Morton RF, Green E, Sanoff HK, McLeod H, Buckner J. NCCTG Study N9741: leveraging learning from an NCI Cooperative Group phase III trial. Oncologist 2009;14:970-8. [PMID: 19828593 DOI: 10.1634/theoncologist.2009-0175] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
Number Citing Articles
1 Basch E, Bennett A, Pietanza MC. Use of patient-reported outcomes to improve the predictive accuracy of clinician-reported adverse events. J Natl Cancer Inst 2011;103:1808-10. [PMID: 22157639 DOI: 10.1093/jnci/djr493] [Cited by in Crossref: 76] [Cited by in F6Publishing: 69] [Article Influence: 7.6] [Reference Citation Analysis]
2 Banerjee AK, Okun S, Edwards IR, Wicks P, Smith MY, Mayall SJ, Flamion B, Cleeland C, Basch E; Patient-Reported Outcomes Safety Event Reporting (PROSPER) Consortium. Patient-Reported Outcome Measures in Safety Event Reporting: PROSPER Consortium guidance. Drug Saf 2013;36:1129-49. [PMID: 24092596 DOI: 10.1007/s40264-013-0113-z] [Cited by in Crossref: 63] [Cited by in F6Publishing: 50] [Article Influence: 9.0] [Reference Citation Analysis]
3 Yoong J, Seah JA, Hamilton K, Teo LN, Chong G. Mortality within 30 days of receiving systemic anti-cancer therapy at a regional oncology unit: what have we learned? Asia Pac J Clin Oncol 2012;8:325-9. [PMID: 22897423 DOI: 10.1111/j.1743-7563.2011.01498.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
4 Sharma MR, Gray E, Goldberg RM, Sargent DJ, Karrison TG. Resampling the N9741 trial to compare tumor dynamic versus conventional end points in randomized phase II trials. J Clin Oncol 2015;33:36-41. [PMID: 25349295 DOI: 10.1200/JCO.2014.57.2826] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 1.9] [Reference Citation Analysis]
5 Bose D, Zimmerman LJ, Pierobon M, Petricoin E, Tozzi F, Parikh A, Fan F, Dallas N, Xia L, Gaur P, Samuel S, Liebler DC, Ellis LM. Chemoresistant colorectal cancer cells and cancer stem cells mediate growth and survival of bystander cells. Br J Cancer 2011;105:1759-67. [PMID: 22045189 DOI: 10.1038/bjc.2011.449] [Cited by in Crossref: 44] [Cited by in F6Publishing: 46] [Article Influence: 4.4] [Reference Citation Analysis]
6 Jazić I, Schrag D, Sargent DJ, Haneuse S. Beyond Composite Endpoints Analysis: Semicompeting Risks as an Underutilized Framework for Cancer Research. J Natl Cancer Inst 2016;108:djw154. [PMID: 27381741 DOI: 10.1093/jnci/djw154] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
7 Meyer AM, Carpenter WR, Abernethy AP, Stürmer T, Kosorok MR. Data for cancer comparative effectiveness research: past, present, and future potential. Cancer 2012;118:5186-97. [PMID: 22517505 DOI: 10.1002/cncr.27552] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.0] [Reference Citation Analysis]
8 Marshall TF, Alfano CM, Sleight AG, Moser RP, Zucker DS, Rice EL, Silver JK, Raj VS, Fu JB, Padgett LS, Lyons KD, Radomski MV, Mckenna R, Pergolotti M. Consensus-Building efforts to identify best tools for screening and assessment for supportive services in oncology. Disability and Rehabilitation 2020;42:2178-85. [DOI: 10.1080/09638288.2018.1555621] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
9 Cohen DR, Todd S, Gregory WM, Brown JM. Adding a treatment arm to an ongoing clinical trial: a review of methodology and practice. Trials 2015;16:179. [PMID: 25897686 DOI: 10.1186/s13063-015-0697-y] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]